R. Ritschard

发表

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Gerhard Christofori, Richard Herrmann, 2011, Clinical Cancer Research.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

D. Fabbro, L. Cascione, D. Rossi, 2017, Clinical Cancer Research.

A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors.

L. Bubendorf, R. Herrmann, C. Mamot, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

R. Herrmann, C. Mamot, C. Rochlitz, 2006, Journal of drug targeting.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells

R. Herrmann, C. Mamot, C. Rochlitz, 2012, Journal of drug targeting.

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

C. Mamot, C. Rochlitz, A. Wicki, 2015, International journal of pharmaceutics.

Gene dosage by quantitative real-time PCR.

C. Rochlitz, J. Boulay, L. Terracciano, 1999, BioTechniques.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

R. Herrmann, H. Hawle, S. Dimitrijević, 2018, European journal of cancer.

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

K. Zaman, R. Winterhalder, C. Mamot, 2023, Scientific Reports.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

C. Genoud, F. Orso, D. Taverna, 2017, Oncotarget.

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Andreas Wicki, Richard Herrmann, Lukas Bubendorf, 2012, The Lancet. Oncology.

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

K. Alitalo, G. Christofori, C. Mamot, 2016, Journal of drug targeting.

Targeting immunoliposomes to EGFR-positive glioblastoma

G. Hutter, C. Mamot, C. Rochlitz, 2022, ESMO open.

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity

P. Herzig, A. Zippelius, R. Mohanlal, 2021, Frontiers in Oncology.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells

R. Herrmann, C. Mamot, C. Rochlitz, 2012, Journal of drug targeting.